Drug Trial Radar · NCT06737536
A First-in-human Research Study on How NNC0662-0419 Works in People Living With Overweight or Obesity
Last checked: Nov 20, 2026Latest source record: Sep 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
100
Actual
Start
Dec 18, 2024
Primary completion
Jul 26, 2025
Study completion Jul 26, 2025
Sponsor
- Lead sponsor
- Novo Nordisk A/SNovo Nordisk (NVO)
- Sponsor type
- Industry
- First posted
- Dec 17, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 19 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is testing a new study medicine which may be used to treat people living with overweight or obesity. The purpose of the study is to see if the new study medicine is safe, how it works in human body and what human body does to the study medicine. Participants will either get the study medicine NNC0662-0419 or placebo (a "dummy" medicine without any active ingredients) given by study staff as an injection under participants skin. Which treatment participants will get is decided by chance. NNC0662-0419 is a new medicine, which cannot be prescribed by doctors. This is the first time the medicine is being given to humans. The study will last for about 9 months.
Conditions
- Overweight
- Obesity
Interventions
NNC0662-0419Drug
Participants will receive NNC0662-0419 subcutaneous (s.c.) once weekly.
Placebo (NNC0662-0419)Other
Participants will receive placebo matched to NNC0662-0419 s.c. once weekly.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Number of treatment emergent adverse events (TEAE)Time frame: From timing of dosing on day 1 until completion of the end of study visit (up to 6 weeks)
- Part B: Number of treatment-emergent adverse events (TEAE)Time frame: From timing of dosing on day 1 until completion of the end of study visit (up to 9 weeks)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Celerion, Lincoln
Lincoln, Nebraska
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.